



ALK  
Investor Relations Department  
BÅ,ge Alle 6-8  
Horsholm DK-2970  
Denmark

Visit IR website [↗](#)  
Sign-up for Email alerts [↗](#)

#### OMX: ALKB

|               |  |
|---------------|--|
| Last Trade:   | 739.00   |
| Trade Time:   | 4:59 PM ET<br>Mar 23, 2018                         |
| Change:       | -2.00 <span style="color: red;">↓</span> (-0.270%) |
| Day Range     | 728.00 - 739.00                                    |
| 52-Week Range | 646.00 - 1133.00                                   |
| Volume        | 1,271,900  |

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

ALK is the world leader in allergy vaccination (immunotherapy). It is the goal of ALK to increase the awareness of the company and its activities through a structured, ongoing, timely and balanced dialogue with investors, shareholders and other stakeholders. It is also a company goal to secure the liquidity of the company's shares and to generate reasonable, long-term returns to shareholders through share price increases and dividends.... [\(more\)](#)

## Company releases [\[ View all \]](#)

*Mar 20, 2018*  
[Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff](#)

*Mar 20, 2018*  
[Grant of share options and performance shares to members of the Board of Management and key employees](#)

*Mar 16, 2018*  
[Articles of Association](#)

*Mar 12, 2018*  
[Annual General Meeting in ALK-Abelló A/S held on 12 March 2018](#)

*Mar 2, 2018*  
[Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff](#)

## Upcoming Events [\[ View all \]](#)

*May 4, 2018*  
[Three-month interim report \(Q1\) 2018](#)

*Aug 15, 2018*  
[Six-month interim report \(Q2\) 2018](#)